DHR Stock Analysis: Buy, Sell, or Hold?
DHR - Danaher Corporation
$218.89
-0.73 (-0.33%)
▼
HOLD
LOW Confidence
Last Updated: January 30, 2026
Earnings: Apr 20, 2026
Get Alerted When DHR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called DHR this week
0% bullish • 1 bearish
0% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: DHR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: DHR shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$326.72
Based on 7.2% avg growth
INTRINSIC VALUE TODAY
$202.87
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DHR is currently trading at $218.89, which is considered oversold relative to its 30-day fair value range of $227.59 to $238.88. From a valuation perspective, the stock is trading at a discount (Forward PE: 23.7) compared to its historical average (27.4). Remarkably, the market is currently pricing in an annual earnings decline of 4.7% over the next few years. This pessimistic expectation contrasts with the company's recent 13.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, DHR is showing support break momentum. The price is currently testing key support at $217.31. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $263.27 (+19.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DHR is showing support break momentum. The price is currently testing key support at $217.31. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $263.27 (+19.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$227.59 -
$238.88
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
Protect Your Profits
Holding DHR? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($263.27)
- CAUTION: Recommendation downgraded due to -6.9% 5-day decline
Fair Price Analysis
30-Day Fair Range
$227.59 -
$238.88
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$217.31
Resistance Level
$242.80
Current Trend
Support Break
Fundamental Context
Forward P/E (Next Year Est.)
23.71
Wall Street Target
$263.27
(+19.9%)
Revenue Growth (YoY)
4.4%
Earnings Growth (YoY)
13.4%
Profit Margin
14.7%
Valuation Discount vs History
-4.7% cheaper
PE vs Historical
23.7 vs 27.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.7%
(market-implied from PE analysis)
1-Year Target
$209.30
(-5%)
2-Year Target
$199.46
(-9%)
3-Year Target
$190.09
(-13%)
3-Yr Target (if PE normalizes)
(PE: 24→27)
$219.67
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 23.7, Growth: 10.3%)
$294.89
(+34%)
Base:
(SPY PE: 22.3, Growth: 10.3%)
$277.36
(+26%)
Bear:
(PE: 19.0, Growth: 10.3%)
$235.75
(+7%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (45x PE), but valuation improves significantly next year (24x PE) as earnings recover.
Trailing PE: 44.64 | Current EPS (TTM): $5.03
Bull Case
$454.84
(+108%)
Analyst growth 84.2%, PE expands to 49.1
Base Case
$413.49
(+89%)
Market implied 84.2%, PE stable at 44.6
Bear Case
$152.69
(-30%)
Severe decline -20.0%, PE contracts to 37.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 23.7 to 27.4
Stabilization Target:
$253.80
(+15.6%)
PE Expansion Potential:
+15.6%
Last updated: January 31, 2026 1:38 AM ET
Data refreshes hourly during market hours. Next update: 2:38 AM
Data refreshes hourly during market hours. Next update: 2:38 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DHR showing a specific setup today?
Insider Activity (6 Months)
5
Buys
5
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
SELL
2025-09-29
Lisa C. McClain
SELL
2025-09-25
Michael T. McCaul
BUY
2025-09-25
Featured in Portfolios
DHR is a key holding in these high-performance investment strategies.
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$653 | 47 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 57 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$121 | 62 BUY |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$257 | 58 HOLD |
|
IQV
IQVIA Holdings Inc |
BUY
23 analysts |
$261 | 59 HOLD |
Advanced DHR Option Strategies
Professional options setups generated by AI based on today's DHR price and gamma walls.
